Latest Headlines

  1. UCB Selects Gwinnett County For New U.S. Biologics Manufacturing Facility 8/20/2026

    UCB today announced that it has selected Gwinnett County, Georgia as the location for its new U.S. biologics manufacturing facility. The campus will be state-of-the art, using a digital-first approach by leveraging AI, robotics, and automation while being natural resources efficient. The project represents a major milestone in UCB’s previously announced U.S. expansion and reinforces the company’s long-term commitment to patients, innovation, and sustainable growth in one of its fastest-growing markets.

  2. Nordson MEDICAL Introduces The New Divert™ ULTRA Line Of Ultra-High- Pressure Stopcocks For Demanding Medical Applications 8/19/2026

    Nordson MEDICAL introduces Divert™ ULTRA, ultra-high-pressure stopcocks engineered for reliable flow control, ergonomic operation, and precision in demanding medical applications up to 1,500 psi.

  3. New Distek Software Simplifies Bioreactor Data Monitoring And Management 8/12/2026

    Distek, Inc., a leading manufacturer of bioprocessing equipment, announces the release of their BIOne Core Software, an advanced, cloud-based historian software platform designed exclusively for BIOne Bioprocess Controllers. Delivered as a Software-as-a-Service (SaaS) solution, BIOne Core enables users to easily visualize, monitor, and manage critical bioprocess data while minimizing on-premise IT infrastructure.

  4. ILC Dover Introduces EZJetFlo™ Technology To Transform Powder Dissolution And Mixing In Biopharmaceutical Manufacturing 8/7/2026
  5. Tasrif Pharmaceutical Granted Second U.S. Patent For CD155-Targeting Antibody Developed With Abzena's Humanization & Immunogenicity Platforms 7/31/2026

    On July 29, 2026, Abzen’s customer Tasrif Pharmaceutical, LLC announced the grant of its second U.S. Patent, expanding its intellectual property targeting the Poliovirus Receptor (CD155/PVR). 

  6. Abzena's Customer Promatix Awarded An Innovate UK Biomedical Catalyst Grant To Advance Cis-Bispecific ADC 7/31/2026

    On July 28, 2026, Promatix Biosciences Ltd, an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, announced that it has been awarded a grant under the Innovate UK Biomedical Catalyst 2025: Industry-led R&D small projects competition. 

  7. Virtual Pharma Expo Launches Searchable Six-Year Equipment Demo Archive Ahead Of September Solid Dosage Event 7/30/2026

    Virtual Pharma Expo has launched a redesigned website that gives pharmaceutical manufacturing teams one place to watch every past equipment demonstration and register for upcoming live events.

  8. AGC Biologics Lands Commercial Manufacturing Agreement For Yokohama Site Worth Hundreds Of Millions Of Dollars 7/28/2026

    Ahead of the official opening of AGC Biologics’ Yokohama site, an international biopharmaceutical company has already secured half of the facility’s mammalian manufacturing capacity with a multi-year commercial contract expected to reach hundreds of millions of dollars in total value. 

  9. New Carrying Straps Simplify Handling Of Meissner's 16 L CryoVault® Container 7/27/2026
  10. Kyverna Therapeutics And ElevateBio Enter Into Commercial Manufacturing And Supply Agreement For Miv-cel 7/27/2026

    Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19 directed CAR T-cell therapy.